CoChat

Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma

Open access
Eskiocak, Ugur, Ramesh, Vijayashree, Gill, Jennifer G., Zhao, Zhiyu, Yuan, Stacy W., Wang, Meng, Vandergriff, Travis, Shackleton, Mark, Quintana, Elsa, Frankel, Arthur E., Johnson, Timothy M., DeBerardinis, Ralph J., Morrison, Sean J. · 2016 · Nature Communications
Cited by 63

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

New therapies are required for melanoma. Here, we report that multiple cardiac glycosides, including digitoxin and digoxin, are significantly more toxic to human melanoma cells than normal human cells. This reflects on-target inhibition of the ATP1A1 Na+/K+ pump, which is highly expressed by melanoma. MEK inhibitor and/or BRAF inhibitor additively or synergistically combined with digitoxin to induce cell death, inhibiting growth of patient-derived melanomas in NSG mice and synergistically extending survival. MEK inhibitor and digitoxin do not induce cell death in human melanocytes or haematopoietic cells in NSG mice. In melanoma, MEK inhibitor reduces ERK phosphorylation, while digitoxin disrupts ion gradients, altering plasma membrane and mitochondrial membrane potentials. MEK inhibitor and digitoxin together cause intracellular acidification, mitochondrial calcium dysregulation and ATP depletion in melanoma cells but not in normal cells. The disruption of ion homoeostasis in cancer cells can thus synergize with targeted agents to promote tumour regression in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms12336

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 45

  1. Cohen, C. et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8, 3728–3733 (2002).
  2. Ong, C. C. et al. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J. Natl Cancer. Inst. 105, 606–607 (2013). · DOI
  3. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006). · DOI · Paper page
  4. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010). · DOI · Paper page
  5. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010). · DOI · Paper page
  6. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012). · DOI · Paper page
  7. Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598 (2008). · DOI · Paper page
  8. Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510–523 (2010). · DOI · Paper page
  9. Quintana, E. et al. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci. Transl. Med. 4, 159ra149 (2012). · DOI · Paper page
  10. López-Lázaro, M. et al. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J. Nat. Prod. 68, 1642–1645 (2005). · DOI · Paper page
  11. Lin, Y., Dubinsky, W. P., Ho, D. H., Felix, E. & Newman, R. A. Determinants of human and mouse melanoma cell sensitivities to oleandrin. J. Exp. Ther. Oncol. 7, 195–205 (2008).
  12. Mijatovic, T. et al. Cardiotonic steroids on the road to anti-cancer therapy. Biochim. Biophys. Acta 1776, 32–57 (2007).
  13. Rahimtoola, S. H. & Tak, T. The use of digitalis in heart failure. Curr. Probl. Cardiol. 21, 781–853 (1996). · DOI
  14. Platz, E. A. et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. 1, 68–77 (2011). · DOI · Paper page
  15. Stenkvist, B. et al. Cardiac glycosides and breast cancer, revisited. N. Engl. J. Med. 306, 484–488 (1982).
  16. Ahern, T. P., Lash, T. L., Sørensen, H. T. & Pedersen, L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res. 10, R102 (2008). · DOI
  17. Biggar, R. J., Wohlfahrt, J., Oudin, A., Hjuler, T. & Melbye, M. Digoxin use and the risk of breast cancer in women. J. Clin. Oncol. 29, 2165–2170 (2011). · DOI · Paper page
  18. Niraula, S. et al. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Canad. Urol. Assoc. J. 2, 1–8 (2011).
  19. Menger, L. et al. Trial watch: cardiac glycosides and cancer therapy. Oncoimmunology 2, e23082 (2013). · DOI · Paper page
  20. Smith, T. W. Contribution of quantitative assay technics to the understanding of the clinical pharmacology of digitalis. Circulation 46, 188–199 (1972). · DOI
  21. Wolff, C., Fuks, B. & Chatelain, P. Comparative study of membrane potential-sensitive fluorescent probes and their use in ion channel screening assays. J. Biomol. Screen. 8, 533–543 (2003). · DOI
  22. Talantov, D. et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 11, 7234–7242 (2005). · DOI · Paper page
  23. Kabbarah, O. et al. Integrative genome comparison of primary and metastatic melanomas. PLoS ONE 5, e10770 (2010). · DOI · Paper page
  24. Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015). · DOI · Paper page
  25. Bortner, C. D., Gomez-Angelats, M. & Cidlowski, J. A. Plasma membrane depolarization without repolarization is an early molecular event in anti-Fas-induced apoptosis. J. Biol. Chem. 276, 4304–4314 (2001). · DOI
  26. Hiyoshi, H. et al. Quiescence and γH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase. Br. J. Cancer. 106, 1807–1815 (2012). · DOI
  27. Parmenter, T. J. et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Disco. 4, 423–433 (2014). · DOI · Paper page
  28. Moor, A. N. & Fliegel, L. Protein kinase-mediated regulation of the Na(+)/H(+) exchanger in the rat myocardium by mitogen-activated protein kinase-dependent pathways. J. Biol. Chem. 274, 22985–22992 (1999). · doi:10.1074/jbc.274.33.22985
  29. Luo, J., Kintner, D. B., Shull, G. E. & Sun, D. ERK1/2-p90RSK-mediated phosphorylation of Na+/H+ exchanger isoform 1. A role in ischemic neuronal death. J. Biol. Chem. 282, 28274–28284 (2007). · DOI
  30. van Erp, P. E., Jansen, M. J., de Jongh, G. J., Boezeman, J. B. & Schalkwijk, J. Ratiometric measurement of intracellular pH in cultured human keratinocytes using carboxy-SNARF-1 and flow cytometry. Cytometry 12, 127–132 (1991). · DOI
  31. Dolz, M., O'Connor, J.-E. & Lequerica, J. L. Flow cytometric kinetic assay of the activity of Na+/H+ antiporter in mammalian cells. Cytometry A 61, 99–104 (2004). · DOI
  32. Grinstein, S., Rotin, D. & Mason, M. J. Na+/H+ exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation. Biochim. Biophys. Acta 988, 73–97 (1989). · DOI · Paper page
  33. Palmer, L. G. & Frindt, G. Amiloride-sensitive Na channels from the apical membrane of the rat cortical collecting tubule. Proc. Natl Acad. Sci. USA 83, 2767–2770 (1986). · DOI · Paper page
  34. Tang, C. M., Presser, F. & Morad, M. Amiloride selectively blocks the low threshold (T) calcium channel. Science 240, 213–215 (1988). · DOI · Paper page
  35. Kim, D. & Smith, T. W. Cellular mechanisms underlying calcium-proton interactions in cultured chick ventricular cells. J. Physiol. 398, 391–410 (1988). · DOI
  36. Burns, K. D., Homma, T., Breyer, M. D. & Harris, R. C. Cytosolic acidification stimulates a calcium influx that activates Na(+)-H+ exchange in LLC-PK1. Am. J. Physiol. 261, F617–F625 (1991).
  37. Minta, A., Kao, J. P. & Tsien, R. Y. Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. J. Biol. Chem. 264, 8171–8178 (1989). · DOI · Paper page
  38. Yoon, J. C. et al. GLTSCR2/PICT1 links mitochondrial stress and Myc signaling. Proc. Natl Acad. Sci. USA 111, 3781–3786 (2014). · DOI
  39. Sena, L. A. & Chandel, N. S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell. 48, 158–167 (2012). · DOI · Paper page
  40. Eruslanov, E. & Kusmartsev, S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol. Biol. 594, 57–72 (2010). · DOI · Paper page
  41. Gerboth, G. D., Effros, R. M., Roman, R. J. & Jacobs, E. R. pH-induced calcium transients in type II alveolar epithelial cells. Am. J. Physiol. 264, L448–L457 (1993).
  42. Grillo-Hill, B. K., Choi, C., Jimenez-Vidal, M. & Barber, D. L. Increased H(+) efflux is sufficient to induce dysplasia and necessary for viability with oncogene expression. eLife 4, e03270 (2015). · DOI
  43. Falchook, G. S. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782–789 (2012). · DOI · Paper page
  44. Choi, M. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768–772 (2011). · DOI · Paper page
  45. Matsuyama, S., Llopis, J., Deveraux, Q. L., Tsien, R. Y. & Reed, J. C. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat. Cell. Biol. 2, 318–325 (2000). · DOI · Paper page

Cited by

See all 63

Metadata

Authors
Eskiocak, U., Ramesh, V., Gill, J. G., Zhao, Z., Yuan, S. W., Wang, M., Vandergriff, T., Shackleton, M., Quintana, E., Frankel, A. E., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J.
Venue
Nature Communications
Published
2016-08-22
Volume
7
Issue
1
Pages
12336-12336
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2516611199
Cited by
63
References
18
FWCI
3.01
Type
journal article
Language
en
Update notices
erratum (2016-09-29)
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. https://app.cochat.ai/papers/10.1038/ncomms12336
The paper
Eskiocak, U., Ramesh, V., Gill, J. G., Zhao, Z., Yuan, S. W., Wang, M., Vandergriff, T., Shackleton, M., Quintana, E., Frankel, A. E., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2016). Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. https://doi.org/10.1038/ncomms12336

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.